Sebastian K S Begg1, David J Birnbaum1, Jeffrey W Clark2, Mari Mino-Kenudson3, Ulrich F Wellner4, Oliver Schilling5, Keith D Lillemoe1, Andrew L Warshaw1, Carlos FernÁndez-Del Castillo1, Andrew S Liss6. 1. Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A. 2. Department of Hematology/Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A. 3. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A. 4. Department of Surgery, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany. 5. Institute of Surgical Pathology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 6. Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A. aliss@mgh.harvard.edu.
Abstract
BACKGROUND/AIM: FOLFIRINOX [fluorouracil (5-FU), irinotecan, oxaliplatin] and gemcitabine plus nab-paclitaxel are standard treatments for patients with pancreatic ductal adenocarcinoma (PDAC). Despite efficacy rates of less than 32%, evidence is lacking to guide the use of one drug over the other. Herein, we compared the sensitivity of patient-derived PDAC cell lines to each of these regimens. MATERIALS AND METHODS: Changes in the growth of 19 low-passage patient-derived PDAC cell lines were evaluated in response to treatment with FOLFIRINOX and gemcitabine plus paclitaxel (Gem-Pac). RESULTS: Six cell lines exhibited optimal sensitivity (high EMax and low GI50) to FOLFIRINOX and three cell lines exhibited optimal sensitivity to Gem-Pac. Several cell lines that were optimally sensitive to one drug regimen exhibited very poor response to the other. CONCLUSION: Further characterization of cancer cells exhibiting preferential sensitivity to each of these regimens may allow the identification of biomarkers to guide the selection of appropriate chemotherapy for a given patient. Copyright
BACKGROUND/AIM: FOLFIRINOX [fluorouracil (5-FU), irinotecan, oxaliplatin] and gemcitabine plus nab-paclitaxel are standard treatments for patients with pancreatic ductal adenocarcinoma (PDAC). Despite efficacy rates of less than 32%, evidence is lacking to guide the use of one drug over the other. Herein, we compared the sensitivity of patient-derived PDAC cell lines to each of these regimens. MATERIALS AND METHODS: Changes in the growth of 19 low-passage patient-derived PDAC cell lines were evaluated in response to treatment with FOLFIRINOX and gemcitabine plus paclitaxel (Gem-Pac). RESULTS: Six cell lines exhibited optimal sensitivity (high EMax and low GI50) to FOLFIRINOX and three cell lines exhibited optimal sensitivity to Gem-Pac. Several cell lines that were optimally sensitive to one drug regimen exhibited very poor response to the other. CONCLUSION: Further characterization of cancer cells exhibiting preferential sensitivity to each of these regimens may allow the identification of biomarkers to guide the selection of appropriate chemotherapy for a given patient. Copyright
Authors: Taylor J Allen-Coyle; Jin Niu; Eva Welsch; Neil T Conlon; Weylon Garner; Martin Clynes; Finbarr O'Sullivan; Robert M Straubinger; Donald E Mager; Sandra Roche Journal: AAPS J Date: 2022-10-13 Impact factor: 3.603
Authors: Brianne R O'Leary; Elena K Ruppenkamp; Garett J Steers; Juan Du; Rory S Carroll; Brett A Wagner; Garry R Buettner; Joseph J Cullen Journal: Pancreas Date: 2022-09-13 Impact factor: 3.243
Authors: Štepán Novák; Michal Kolář; Arpád Szabó; Zdena Vernerová; Lukáš Lacina; Hynek Strnad; Jana Šáchová; Miluše Hradilová; Jan Havránek; Michal Španko; Matúš Čoma; Lukáš Urban; Miriam Kaňuchová; Nikola Melegová; Robert Gürlich; Josef Dvořák; Karel Smetana; Peter Gál; Pavol Szabo Journal: Cancer Genomics Proteomics Date: 2021 May-Jun Impact factor: 4.069